Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib dose-escalation study in pediatric relapsed or refractory leukemia or advanced solid tumors
NL-OMON40401Phase 2Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of volasertib in Acute Leukaemia and Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicity. Planned start Nov 2013; status: withdrawn.
02
Drugs
volasertib
03
Conditions
Acute LeukaemiaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40401.